Risk assessment body makes recommendations on Richter's Esmya

Esmya may remain on markets but with restrictions.

ANALYST VIEW - Hungary's Richter gets 'Hold' rating from Jefferies

After release of Q1 earnings report.

Hungary Richter to reveal Q1 results on Tuesday - What to expect?

Analysts are split over after-tax profit.

Hungary pharma Richter posts record-low profit over Esmya

Good news about flagship product of Hungary's Richter

Share price on the rise.

Hungary Richter to pay HUF 68 dividend per share

Annual General Meeting is coming up.

Richter drug wins 2017 Innovation Grand Prize in Hungary

Richter awarded for Cariprazine.

Hungary Richter gets good news about product

European Medicines Agency is not a bearer of bad news only.

FDA extends investigation of flagship product of Hungary's Richter

August is the new date.

ANALYST VIEW - Jefferies downgrades Hungary's Richter over Esmya woes

Slashes target price, removes Esmya from model.

Esmya seen causing HUF 42 billion impairment loss for Hungary’s Richter

Negative impact on 2017 profits.

Last week's bad news to weigh on Hungary's Richter for months - analysts

Jefferies comment EMA probe, Q4 results.

Hungary Richter management see drop in Esmya sales due to probe

Hungary Richter Q417 after-tax profit undershoots even lowest estimate

Profit of Hungary's leading drugs maker plunges.

INSTANT VIEW - EMA recommends temporary measures for Richter’s Esmya

Sentiment to be impacted by cautionary measures.

Key drug of Hungary's Richter subject of temporary EMA measures

Share price drops sharply.

Hungary Richter could cause quite a surprise on Monday

Earnings report expected to show profit contraction.

Hungary Richter drug cariprazine passes Phase III bipolar depression trials

Hungary's Richter reacts to Esmya probe

One of key products under EMA investigation.

European Medicines Agency probes product of Hungary's Richter

Flagship product Emsya under the microscope. Richter reacts.